{"preliminary_commentary":{"by_channel":{"x_thread":47,"bluesky_thread":3,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05078047\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"MOIO","nct_id":"NCT05078047","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=moio-nct05078047. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MOIO","arms":[{"description":"Reduced dose intensity of IO:\n\nIO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision","label":"Experimental arm","type":"EXPERIMENTAL"},{"description":"Standard IO:\n\nContinuation of IO at the same dose levels and rhythmicity until disease progression, unacceptable toxicity, death or patient's choice.","label":"Control arm","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2029-05-07","type":"ESTIMATED"},"conditions":["Lung Cancer Metastatic","Renal Cell Carcinoma","Head and Neck Cancer","Triple Negative Breast Cancer","Merkel Cell Carcinoma","Hepatocellular Carcinoma","Melanoma","Urothelial Carcinoma","Colorectal Carcinoma With Microsatellite Instability","Esophageal Squamous Cell Carcinoma","Endometrial Carcinoma","Cervical Cancer","Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma","Basal Cell Carcinoma","Squamous Skin Carcinoma"],"enrollment":{"count":646,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Reduced dose intensity of IO","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-17","lead_sponsor":"UNICANCER","official_title":"Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-05-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"From randomization to disease progression or death, up to 3 years"}],"references":[{"citation":"Gravis G, Marino P, Olive D, Penault-LLorca F, Delord JP, Simon C, Lamrani-Ghaouti A, Sabatier R, Ciccolini J, Boher JM. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study. BMC Cancer. 2023 May 2;23(1):393. doi: 10.1186/s12885-023-10881-8.","pmid":"37131154","type":"DERIVED"}],"start_date":{"date":"2022-03-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","url":"https://clinicaltrials.gov/study/NCT05078047"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/moio-nct05078047"}